Related Experiment Videos
[Pharmacologic therapy of heart failure]
1Slovenský ústav srdcových a cievnych chorôb v Bratislave. transpl@susch.sk
Bratislavske Lekarske Listy
|November 29, 2001
Summary
Pharmacotherapy for end-stage heart failure in Slovakia shows low ACE inhibitor dosage in routine care. Beta-blocker use significantly increased post-discharge from specialized centers.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Context:
- End-stage heart failure management presents therapeutic challenges.
- Routine cardiologic practice in Slovakia was evaluated.
- Comparison of pharmacotherapy before and after discharge from specialized centers.
Purpose:
- To analyze and compare pharmacotherapy for end-stage heart failure (EF 20.5 +/- 4.1%) in routine Slovak cardiologic practice versus post-discharge care.
- To identify potential discrepancies in medication use and dosage.
Summary:
- A retrospective analysis of 107 patients (11 females) with end-stage heart failure was conducted.
- Medication use at admission versus discharge included: digoxin (94% vs 91%), ACE inhibitors (86% vs 94%), loop diuretics (90% vs 94%), AT-1 antagonists (0% vs 4%), and beta-blockers (23% vs 55%).
- A notable finding was the rather low dosage of ACE inhibitors prescribed in routine practice.
Impact:
- Highlights potential underutilization or suboptimal dosing of key heart failure medications in routine practice.
- Suggests a need for improved guideline adherence and therapeutic strategies in managing advanced heart failure.
- Indicates a positive impact of specialized care on beta-blocker initiation and potentially ACE inhibitor intensification post-discharge.